

June 13, 2025

Izotropic Provides Marketing Update

VANCOUVER and SACRAMENTO, June 13, 2025, Izotropic Corporation (CSE: **IZO**) (OTCQB: **IZOZF**) (FSE: **1R3**) ("**Izotropic**" or the "**Company**"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has entered into an agreement with 1822053 Alberta Ltd. (d/b/a Evolux Capital) ("**Evolux**") to provide marketing services to the Company. The services are expected to include the creation and distribution of social media advertising, development and implementation of communications strategies, assisting with brand development, and coordinating with social media and advertising partners.

Evolux is an arm's-length marketing firm and has been engaged for an initial six-month term, ending December 11, 2025, for a total consideration of 200,000 Restricted Share Units ("**RSUs**"), to be paid in full prior to the commencement of services. The RSUs shall be granted in accordance with the issuer's equity incentive plan and applicable regulatory approvals. Evolux can be contacted at evoluxcapital@gmail.com or 126 Mitchell Crescent, Blackfalds, Alberta, T4M 0H6.

The Company has also issued 60,000 RSUs to certain Consultants.

Pursuant to the Company's Long Term Incentive Plan, 260,000 RSUs have been issued and vest immediately.

About Izotropic:

More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca.

Forward-Looking Statements:

This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.

These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.

Contacts:

Robert Thast, Interim Chief Executive Officer

Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1

Email: bthast@izocorp.com

James Gagnon, International Communications

Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2

General and Corporate Inquiries

Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3

Email: info@izocorp.com